Teneligliptin 20 mg + Metformin 500 mg PCD Pharma

Brand Name

TNBEST-M Tablet (Bilayered)

Composition

Teneligliptin 20mg & Metformin 500mg (Extended Release)

Therapeutic Use

ANTIDIABETICS

Size

10 x 10

Verified Exporter

Verified Seller

Trusted Pharma

Description

TNBEST-M Tablet (Bilayered) contains Teneligliptin 20 mg and Metformin 500 mg extended-release (ER), a combination of two oral antidiabetic agents used to help manage blood glucose levels in adults with type 2 diabetes mellitus when prescribed by a qualified healthcare professional. Teneligliptin belongs to the dipeptidyl peptidase-4 (DPP-4) inhibitor class, while metformin is a biguanide that helps reduce glucose production in the liver and improve the body’s response to insulin.

This bilayered formulation combines two complementary mechanisms of glucose regulation. It may be considered when a clinician determines that combination therapy is appropriate alongside dietary management, physical activity and regular blood glucose monitoring. suitability depends on the patient’s medical history, kidney function, other medicines and the approved product information.

CardianCare focuses on cardiac and diabetic healthcare products for healthcare professionals and pharmaceutical business partners. Businesses searching for a Teneligliptin 20 mg + Metformin 500 mg ER Tablets manufacturer India can enquire about current product availability, approved specifications, manufacturing details and relevant quality documentation.

For procurement teams evaluating a Teneligliptin 20 mg + Metformin 500 mg ER Tablets manufacturer and supplier India, important considerations include the exact composition, extended-release formulation, bilayered Tablet specifications, product authorisation, batch traceability, packaging and commercial supply terms.

2. Key Ingredient

Composition:

Teneligliptin 20 mg + Metformin 500 mg

Teneligliptin 20 mg: Teneligliptin is a DPP-4 inhibitor that prolongs the activity of incretin hormones, including GLP-1 and GIP. These hormones help regulate glucose-dependent insulin secretion and glucagon release, supporting blood glucose control.

Metformin 500 mg ER: Metformin is a biguanide antidiabetic agent. It primarily reduces glucose production in the liver and improves insulin sensitivity. The extended-release formulation is designed to release the medicine over an extended period according to its product specifications.

The combination brings together incretin-based glucose regulation and metformin’s effects on hepatic glucose production and insulin sensitivity. Its suitability should be assessed by the prescribing clinician according to the approved product label.

Businesses researching a Teneligliptin 20 mg + Metformin 500 mg ER pharmaceutical company India should assess the exact active ingredients, release characteristics, manufacturing source, regulatory status and applicable quality documentation.

Companies seeking a Teneligliptin 20 mg + Metformin 500 mg ER medicine manufacturer India should verify product authorisation, manufacturing permissions, batch-specific quality records, formulation details and applicable regulatory requirements before procurement.

3. Key Benefits

Complementary glucose control: Combines two antidiabetic agents with different mechanisms of action to help manage blood glucose in eligible adults with type 2 diabetes.

Incretin hormone support: Teneligliptin helps prolong incretin activity involved in glucose-dependent insulin secretion and glucagon regulation.

Hepatic glucose regulation: Metformin helps reduce glucose production in the liver and improves insulin sensitivity.

Extended-release formulation: The metformin ER component is designed for extended drug release in accordance with the approved formulation.

Bilayered Tablet design: Combines the specified active ingredients in a bilayered dosage form, subject to the product’s approved specifications.

Part of an individualised treatment plan: May support a broader diabetes management strategy involving medical supervision, dietary planning, exercise and glucose monitoring.

The degree of blood glucose improvement varies by patient. No medicine replaces regular monitoring, appropriate nutrition, physical activity or medical follow-up.

Pharmaceutical buyers searching for a Teneligliptin 20 mg + Metformin 500 mg ER supplier India should verify the product’s authenticity, approved composition, availability, shelf life, packaging and supply continuity.

A Teneligliptin 20 mg + Metformin 500 mg ER Tablet wholesaler and distributor India enquiry may involve stock availability, minimum order quantities, distribution eligibility, delivery coverage and applicable commercial terms.

Businesses seeking a Teneligliptin 20 mg + Metformin 500 mg ER bulk supplier India should request a formal quotation and confirm batch traceability, storage conditions, packaging specifications and quality documentation.

A Teneligliptin 20 mg + Metformin 500 mg ER pharmaceutical distributor India should verify relevant licensing requirements, product availability and approved promotional information before beginning commercial activities.

4. How Does It Work?

The two active ingredients act through different pathways to support blood glucose regulation.

Teneligliptin inhibits the DPP-4 enzyme, which breaks down incretin hormones. By prolonging their activity, it helps support glucose-dependent insulin secretion and regulate glucagon release when blood glucose levels are elevated.

Metformin primarily reduces glucose production in the liver and improves the body’s response to insulin. This helps reduce excessive glucose release into the bloodstream and supports glycaemic management.

Together, these mechanisms can provide complementary glucose-lowering effects in eligible adults with type 2 diabetes. Hypoglycaemia risk may increase when the combination is used with insulin or sulfonylureas. Metformin also requires particular attention to kidney function and the risk of lactic acidosis in susceptible patients.

5. Directions for Use

Dosage: Take only as prescribed by a qualified doctor. The appropriate regimen depends on previous treatment, blood glucose control, kidney function and the approved product label.

Administration: Follow the approved product instructions for taking this bilayered Tablet. Because it contains extended-release metformin, do not crush, chew or split the Tablet unless the approved product information specifically permits this.

With food: Metformin ER is commonly taken with food to improve gastrointestinal tolerability, but follow the exact directions supplied with the product and the prescriber’s advice.

Regular timing: Follow the prescribed schedule consistently. Do not change the dose or timing without medical advice.

Kidney assessment: Kidney function should be assessed before treatment and monitored as clinically appropriate.

Other medicines: Inform the doctor about insulin, sulfonylureas and all other prescription medicines, over-the-counter products and supplements.

Missed dose: Follow the patient leaflet or ask a pharmacist or doctor for advice. Do not take a double dose to compensate for a missed dose.

Monitoring: Continue recommended blood glucose monitoring, dietary measures, physical activity and follow-up appointments.

Do not stop or alter diabetes treatment independently. The prescriber should determine whether this combination is suitable for the individual patient.

6. Possible Side Effects

Possible side effects may include:

Nausea

Diarrhoea

Abdominal discomfort

Bloating or gas

Reduced appetite

Vomiting or indigestion

Metformin-related gastrointestinal symptoms may be more noticeable when treatment begins or the dose changes. Taking the medicine as directed with food may help where specified by the approved product information.

Important adverse reactions and warning signs include:

Hypoglycaemia: The risk can increase when used with insulin or sulfonylureas. Recognise symptoms such as sweating, shakiness, dizziness, confusion or unusual weakness.

Lactic acidosis: A rare but potentially life-threatening complication associated with metformin. Severe weakness, muscle pain, breathing difficulty, unusual sleepiness or abdominal symptoms require urgent medical attention.

Vitamin B12 deficiency: Long-term metformin use may reduce vitamin B12 levels in some patients. Monitoring may be appropriate when clinically indicated.

Pancreatitis: Severe, persistent abdominal pain, particularly if it radiates to the back, requires urgent medical assessment.

Allergic reactions: Serious swelling, breathing difficulty or a severe rash requires emergency care.

Dehydration or acute illness: Significant vomiting, diarrhoea or reduced fluid intake can affect kidney function and increase treatment-related risks.

This list is not exhaustive. Consult a healthcare professional about persistent or concerning symptoms and refer to the approved product information for the full safety profile.

7. Safety Information

Medical supervision: Use only under the guidance of a qualified healthcare professional.

Allergies: Do not use if there is a known serious allergy to either active ingredient or any component of the formulation.

Kidney health: Metformin may be unsuitable in severe renal impairment. Kidney function must be assessed before treatment and monitored as advised.

Liver health: Inform the prescriber about liver disease because it may increase the risk of metformin-associated lactic acidosis.

Acute illness and dehydration: Severe infection, persistent vomiting or diarrhoea, dehydration or reduced food and fluid intake may require temporary treatment review by a clinician.

Surgery and contrast procedures: Tell the healthcare team about metformin use before surgery or imaging procedures involving iodinated contrast. The clinician will advise whether temporary interruption is needed.

Alcohol: Avoid excessive alcohol intake and discuss alcohol use with the doctor because it can increase the risk of metformin-associated lactic acidosis.

Pancreatic symptoms: Seek urgent assessment if severe, persistent abdominal pain suggests pancreatitis.

Pregnancy and breastfeeding: Consult a doctor before use during pregnancy, when planning pregnancy or while breastfeeding. Diabetes treatment should be reviewed by the clinician.

Drug interactions: Tell the doctor about all medicines, especially insulin, sulfonylureas and medicines that may affect kidney function or blood glucose.

Storage: Store in the original packaging according to the approved label, protected from excessive heat and moisture and out of reach of children.

This information is educational and does not replace approved prescribing information or individual medical advice.

8. B2B Pharmaceutical Business Enquiries

CardianCare focuses on cardiac and diabetic healthcare products for healthcare professionals and pharmaceutical business partners. Pharmaceutical distributors, wholesalers, pharmacists and eligible trade partners should confirm current product availability, approved specifications and commercial arrangements directly with the company.

Businesses researching a Teneligliptin 20 mg + Metformin 500 mg ER PCD pharma franchise India opportunity can enquire about current product listings, partner eligibility, territory terms and applicable business requirements.

For a Teneligliptin 20 mg + Metformin 500 mg ER Tablets PCD pharma franchise enquiry, prospective partners can request information about availability, minimum order requirements, distribution eligibility and any promotional support that may be available.

Companies exploring a Teneligliptin 20 mg + Metformin 500 mg ER Tablet PCD franchise should confirm whether this formulation is included in a current programme before making investment or promotional commitments.

Businesses evaluating Teneligliptin 20 mg + Metformin 500 mg ER third party manufacturing India services should first confirm whether the proposed company offers such arrangements. Relevant checks include manufacturing permissions, product authorisation, applicable GMP compliance, minimum batch quantities and quality documentation.

A Teneligliptin 20 mg + Metformin 500 mg ER Tablet third party manufacturer India enquiry should cover the authorised manufacturing facility, bilayered formulation capabilities, extended-release specifications, quality systems, batch release procedures and packaging requirements.

Companies researching Teneligliptin 20 mg + Metformin 500 mg ER contract manufacturing India should confirm service availability directly with the proposed manufacturing partner. Relevant discussions may include formulation specifications, technical documentation, quality agreements, regulatory responsibilities, manufacturing authorisation and commercial feasibility.

Contact CardianCare through its official website to enquire about current product availability and eligible pharmaceutical business opportunities. Distribution, PCD franchise, third-party manufacturing and contract manufacturing services must be confirmed directly with the company before being represented as available.

For more information about TNBEST-M Tablet (Bilayered) – Teneligliptin 20 mg + Metformin 500 mg ER, click here

Frequently Asked Questions

This combination is intended to help manage blood glucose in adults with type 2 diabetes mellitus when prescribed appropriately. It should be used alongside recommended dietary measures, physical activity and medical monitoring.

The supplied composition is Teneligliptin 20 mg and Metformin 500 mg extended-release (ER). Teneligliptin is a DPP-4 inhibitor, while metformin is a biguanide antidiabetic agent.

Teneligliptin prolongs incretin hormone activity to support glucose-dependent insulin secretion and glucagon regulation. Metformin primarily reduces glucose production in the liver and improves insulin sensitivity.

A bilayered Tablet contains two distinct layers within one dosage form. The actual release design and formulation characteristics must be confirmed against the approved product specifications.

Take it exactly as prescribed and follow the approved product label. Do not crush, chew or split the extended-release bilayered Tablet unless the product information explicitly permits it.

Possible effects include nausea, diarrhoea, abdominal discomfort, bloating and reduced appetite. Important warning signs include symptoms of lactic acidosis, severe abdominal pain, serious allergic reactions or significant hypoglycaemia.

People with kidney or liver disease, dehydration, a history of pancreatitis, significant allergies, pregnancy or breastfeeding considerations, or other major medical conditions should discuss suitability with their healthcare professional.

Additional antidiabetic medicines may sometimes be prescribed as part of an individual treatment plan. However, combining therapies can change the risk of hypoglycaemia and other adverse effects, so the regimen must be reviewed by a clinician.

Verify the exact composition, metformin release characteristics, bilayered dosage form, product authorisation, manufacturing source, quality documentation, batch traceability, shelf life, packaging and commercial terms.

Eligible pharmaceutical businesses can contact CardianCare through its official website to ask about current product availability and applicable distribution or franchise arrangements. Confirm all services, eligibility criteria and commercial terms directly with the company.

Reviews

There are no reviews yet.

Be the first to review “Teneligliptin 20 mg + Metformin 500 mg PCD Pharma”

Your email address will not be published. Required fields are marked *

Enquiry Now
close slider

    Drop us a Line